Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA)

Background Coronavirus Disease 2019 (COVID-19), firstly reported in China last November 2019, became a global pandemic. It has been shown that periods of isolation may induce a spike in alcohol use disorder (AUD). In addition, alcohol-related liver disease (ALD) is the most common consequence of exc...

Full description

Saved in:
Bibliographic Details
Published inDigestive diseases and sciences Vol. 67; no. 6; pp. 1975 - 1986
Main Authors Testino, Gianni, Vignoli, Teo, Patussi, Valentino, Allosio, Pierluigi, Amendola, Maria Francesca, Aricò, Sarino, Baselice, Aniello, Balbinot, Patrizia, Campanile, Vito, Fanucchi, Tiziana, Greco, Giovanni, Macciò, Livia, Meneguzzi, Cristina, Mioni, Davide, Palmieri, Vincenzo Ostilio, Parisi, Michele, Renzetti, Doda, Rossin, Raffaella, Gandin, Claudia, Bottaro, Luigi Carlo, Bernardi, Mauro, Addolorato, Giovanni, Lungaro, Lisa, Zoli, Giorgio, Scafato, Emanuele, Caputo, Fabio
Format Journal Article
LanguageEnglish
Published New York Springer US 01.06.2022
Springer
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0163-2116
1573-2568
1573-2568
DOI10.1007/s10620-021-07006-1

Cover

More Information
Summary:Background Coronavirus Disease 2019 (COVID-19), firstly reported in China last November 2019, became a global pandemic. It has been shown that periods of isolation may induce a spike in alcohol use disorder (AUD). In addition, alcohol-related liver disease (ALD) is the most common consequence of excessive alcohol consumption worldwide. Moreover, liver impairment has also been reported as a common manifestation of COVID-19. Aims The aim of our position paper was to consider some critical issues regarding the management of ALD in patients with AUD in the era of COVID-19. Methods A panel of experts of the Italian Society of Alcohology (SIA) met via “conference calls” during the lockdown period to draft the SIA’s criteria for the management of ALD in patients with COVID-19 as follows: (a) liver injury in patients with ALD and COVID-19 infection; (b) toxicity to the liver of the drugs currently tested to treat COVID-19 and the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) reorganization of the management of compensated and decompensated ALD and liver transplantation in the COVID-19 era. Results and Conclusions The COVID-19 pandemic has rapidly carried us toward a new governance scenario of AUD and ALD which necessarily requires an in-depth review of the management of these diseases with a new safe approach (management of out-patients and in-patients following new rules of safety, telemedicine, telehealth, call meetings with clinicians, nurses, patients, and caregivers) without losing the therapeutic efficacy of multidisciplinary treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0163-2116
1573-2568
1573-2568
DOI:10.1007/s10620-021-07006-1